Dual‐targeting therapy against HER3/MET in human colorectal cancers

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 8; pp. 9684 - 9696
• Main Authors: Yamasaki, Akitaka, Miyake, Rikuto, Hara, Yuta, Okuno, Hideki, Imaida, Takuya, Okita, Kouki, Okazaki, Shogo, Akiyama, Yasutoshi, Hirotani, Kenji, Endo, Yuichi, Masuko, Kazue, Masuko, Takashi, Tomioka, Yoshihisa
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2023; John Wiley and Sons Inc; Wiley
• Subjects: Animals; Antibodies; c-Met protein; Cancer therapies; Cell culture; Cell Line, Tumor; Cell Proliferation; Cell surface; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Forkhead Box protein M1; Forkhead protein; Glycerol; Growth factors; Hepatocyte growth factor; human epidermal growth factor receptor family; Humans; Immunohistochemistry; Kinases; Laboratory animals; Malignancy; Membrane proteins; Membranes; mesenchymal to epithelial transition factor; Mice; Mice, Nude; Neuregulin 1; Phosphorylation; Proteins; Signal Transduction; Tumors; Tyrosine; United States > US; Japan; human epidermal growth factor receptor family; Forkhead Box protein M1; colorectal cancer; mesenchymal to epithelial transition factor

Background Colorectal cancer (CRC) is the most common malignancy in the world, and novel molecular targeted therapies for CRC have been vigorously pursued. We searched for novel combination therapies based on the expression patterns of membrane proteins in CRC cell lines. Results A positive correlat...